HIGHLIGHTS
SUMMARY
The median age at diagnosis for lung cancer patients is about 70 years old; at diagnosis, roughly 50-60% of patients are already metastatic (stage IV), 20-25% of patients present a locally advanced disease (stage III), and 20-25% of patients present an early-stage disease (stage I/II). RET-selective TKIs (selpercatinib and pralsetinib) have revolutionized the landscape of RET+ advanced NSCLC treatment thanks to their efficacy and safety profiles, and currently represent the standard of care for both naïve patients and patients that have not received a selective RET-TKI . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.